 BetterLife Pharma Inc CSE:BETR OTCQB:BETRF FRA:NPAU announced that it has applied for patent protection for a novel implant device designed to prevent the potential side effects of patients self-administering more psilocybin or LSD than prescribed for in mental health treatment. LSD and psilocybin microdosing is currently in multiple ongoing clinical trials, the company noted, and one issue it says is being majorly overlooked is the possibility of a patient consuming a full psychedelic dose of psilocybin or LSD as opposed to the prescribed microdose, or the resale of the drugs to someone other than the patient. 